Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT03783416 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

SIZOMUS Safety of Ixazomib Targeting Plasma Cells in Multiple Sclerosis

Study acronym: SIZOMUS
StatusRecruiting
PhasePhase 1
Started
View on ClinicalTrials.gov ↗
Trial flagged as At Risk
Primary completion moved at least 12 months later Jul 31, 2026 → Jul 31, 2027
See other at-risk trials from Queen Mary University of London

Record History

  1. Primary and study completion pushed from Jul 31, 2026 to Jul 31, 2027v7
  2. Primary completion date: Jun 30, 2025 to Jul 31, 2026
    • Study completion date: Aug 31, 2025 to Jul 31, 2026
    v6
  3. Primary completion date: Aug 31, 2024 to Jun 30, 2025
    • Study completion date: Aug 31, 2024 to Aug 31, 2025
    v5
  4. Primary and study completion dates: Aug 20, 2023 to Aug 31, 2024
    • Start date: Aug 20, 2020 to Jun 15, 2020
    v4
  5. Trial status: Not Yet Recruiting to Recruitingv3 Show 4 more changesShow less
    • Primary completion date: Jun 1, 2022 to Aug 20, 2023
    • Start date changed from estimate of Jun 1, 2019 to Aug 20, 2020
    • Study completion date: Jun 1, 2023 to Aug 20, 2023
    • Site details revised
  6. Re-verified, no change to tracked fieldsv2
  7. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
The study seeks to investigate safety and efficacy of ixazomib (NINLARO), a proteasome inhibitor, in multiple sclerosis (MS). Participants will receive either ixazomib capsules or placebo capsules for up to 24 months.
Trial Details
NCT Number NCT03783416
Lead Sponsor Queen Mary University of London
Collaborators: Takeda Pharmaceuticals International, Inc.
Conditions
(from sponsor)		 Relapsing Remitting Multiple Sclerosis, Primary Progressive Multiple Sclerosis, Secondary Progressive Multiple Sclerosis
Related terms Multiple Sclerosis, Chronic Progressive, Multiple Sclerosis, Relapsing-Remitting
Enrollment 72 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov